Cellectis (CLLS) Current Assets (2014 - 2026)
Cellectis (CLLS) recorded quarterly Current Assets of $204.5 million in Q1 2026, down 13.42% quarter-over-quarter from $236.2 million in Q4 2025, and down 24.75% on a YoY basis from $271.8 million in Q1 2025.
Cellectis (CLLS) Current Assets (2014 - 2026) Analysis & Trends
Cellectis' Current Assets history runs 13 years deep, the most recent figure standing at $204.5 million for Q1 2026.
- In Q1 2026, Current Assets fell 24.75% year-over-year to $204.5 million; the TTM figure through Mar 2026 stood at $204.5 million (down 24.75% YoY), while the FY2025 annual figure was $236.2 million, down 17.7% from the prior year.
- Current Assets was $204.5 million for Q1 2026 at Cellectis, down from $236.2 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $305.8 million in Q2 2024 to a low of $96.5 million in Q3 2023.
- Historically, Current Assets has averaged $206.0 million across 5 years, with a median of $221.2 million in 2025.
- The sharpest annual moves came in 2022 and 2024: Current Assets plunged 45.86% in 2022, then jumped 205.13% in 2024.
- A 5-year view of Current Assets shows it stood at $122.0 million in 2022, then jumped by 90.92% to $233.0 million in 2023, then advanced by 23.2% to $287.1 million in 2024, then slipped by 17.7% to $236.2 million in 2025, then fell by 13.42% to $204.5 million in 2026.
- The last three Current Assets figures came in at $204.5 million (Q1 2026), $236.2 million (Q4 2025), and $221.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.31 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 521.86 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 10.37 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.25 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 3.59 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 7.63 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 11.73 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 600.85 Mn |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | 204.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 204.55 Mn |
| Dec 31, 2025 | 236.24 Mn |
| Sep 30, 2025 | 221.19 Mn |
| Jun 30, 2025 | 230.64 Mn |
| Mar 31, 2025 | 271.83 Mn |
| Dec 31, 2024 | 287.07 Mn |
| Sep 30, 2024 | 294.43 Mn |
| Jun 30, 2024 | 305.80 Mn |
| Mar 31, 2024 | 258.07 Mn |
| Dec 31, 2023 | 233.01 Mn |
| Sep 30, 2023 | 96.49 Mn |
| Jun 30, 2023 | 113.29 Mn |
| Mar 31, 2023 | 117.23 Mn |
| Dec 31, 2022 | 122.04 Mn |
| Sep 30, 2022 | 140.27 Mn |
| Jun 30, 2022 | 175.17 Mn |
| Mar 31, 2022 | 195.18 Mn |
| Dec 31, 2021 | 225.43 Mn |
| Sep 30, 2021 | 235.85 Mn |
| Jun 30, 2021 | 280.35 Mn |